Lana M. Chahine
University of Pittsburgh
70 Papers
52 Citations
Lana M. Chahine is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Parkinson's disease. The author has an hindex of 18, co-authored 70 publications. Previous affiliations of Lana M. Chahine include Georgetown University & University of Pennsylvania.
Chat about Author
Papers
The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort
Kenneth Marek,Sohini Chowdhury,Andrew Siderowf,Shirley Lasch,Christopher S. Coffey,Chelsea Caspell-Garcia,Tanya Simuni,Danna Jennings,Caroline M. Tanner,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Norbert Schuff,Andrew B. Singleton,Karl Kieburtz,Arthur W. Toga,Brit Mollenhauer,Doug R. Galasko,Lana M. Chahine,Daniel Weintraub,Tatiana Foroud,Duygu Tosun-Turgut,Kathleen L. Poston,Vanessa Arnedo,Mark Frasier,Todd Sherer,Parkinson's Progression Markers Initiative +26 more
TL;DR: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease progression markers to accelerate disease‐modifying therapeutic trials.
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Tanya Simuni,Andrew Siderowf,Shirley Lasch,Christopher S. Coffey,Chelsea Caspell-Garcia,Danna Jennings,Caroline M. Tanner,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Norbert Schuff,Andrew B. Singleton,Karl Kieburtz,Arthur W. Toga,Brit Mollenhauer,Doug R. Galasko,Lana M. Chahine,Daniel Weintraub,Tatiana Foroud,Duygu Tosun,Kathleen L. Poston,Vanessa Arnedo,Mark Frasier,Todd Sherer,Sohini Chowdhury,Kenneth Marek +25 more
TL;DR: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD.
186
The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.
Ethan G. Brown,Lana M. Chahine,Samuel M. Goldman,Monica Korell,Emerald Mann,Daniel R. Kinel,Vanessa Arnedo,Kenneth Marek,Caroline M. Tanner +8 more
TL;DR: The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk, and FI provides a rapid, patient-centered means to assess these effects and identify needs that can be used to improve the health of people withPD.
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Brit Mollenhauer,Mohammed Dakna,Niels Kruse,Douglas Galasko,Tatiana Foroud,Henrik Zetterberg,Sebastian Schade,Roland G. Gera,Wenting Wang,Feng Gao,Mark Frasier,Lana M. Chahine,Christopher S. Coffey,Andrew B. Singleton,Tanya Simuni,Daniel Weintraub,John Seibyl,Arthur W. Toga,Caroline M. Tanner,Karl Kieburtz,Kenneth Marek,Andrew Siderowf,Jesse M. Cedarbaum,Samantha J. Hutten,Claudia Trenkwalder,Danielle Graham +25 more
TL;DR: The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker and to evaluate its application in clinical practice.
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Brit Mollenhauer,Chelsea Caspell-Garcia,Christopher S. Coffey,Peggy Taylor,AB Singleton,Leslie M. Shaw,John Q. Trojanowski,Mark Frasier,Tanya Simuni,Alex Iranzo,Wolfgang H. Oertel,Andrew Siderowf,Daniel Weintraub,John Seibyl,Arthur W. Toga,Caroline M. Tanner,Karl Kieburtz,Lana M. Chahine,Kenneth Marek,Douglas Galasko,Ppmi study +20 more
TL;DR: Biomarkers related to α‐synuclein may be informative for PD diagnosis/progression and central to the pathophysiology of PD.